Neoadjuvant chemotherapy using a platinum, vincristine and peplomycin (CVP) combination in patients with carcinoma of the uterine cervix.
Neoadjuvant chemotherapy consisting of a cis-platinum, vincristine and peplomycin (CVP) combination has been used to treat patients with carcinoma of the uterine cervix at our departments since 1983. Twenty-one patients are reviewed in this study. A high response rate (71.4%) was obtained with 19.0% complete and 52.4% partial responses prior to radical therapy. Survival times and the progression free interval for stage I and III disease treated with CVP show improvement compared to patients not treated with CVP. No life-threatening toxicity related to chemotherapy was noted. This combination chemotherapy used in neoadjuvant setting warrants further study.
Shimamoto
T
T
Department of Obstetrics and Gynecology, Miyazaki Prefectural Hospital, Japan.
Tateyama
H
H
Kohso
T
T
Hamada
M
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D017663:Peplomycin / Q000008:administration & dosage; D010984:Platinum / Q000008:administration & dosage; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality; D014750:Vincristine / Q000008:administration & dosage
D010984:Platinum; D017663:Peplomycin; D014750:Vincristine